The Daily Cut (Weight Loss & Metabolic Health) — Sunday, January 18, 2026
Subject: “Jab‑u‑ary” Goes Mainstream + Medicaid Pullbacks + The New Era of Oral Wegovy
Preview text: Supermarkets are redesigning food for GLP‑1 appetites, Medicaid coverage keeps shifting, and the oral GLP‑1 race is heating up.
1) Today’s News Headlines
“Jab‑u‑ary” is no longer just a social media joke—UK supermarkets are rolling out smaller, higher‑protein meals explicitly aimed at people on GLP‑1 medications, reflecting how these drugs are reshaping buying habits. (theguardian.com)
Meanwhile, access remains uneven: Medicaid coverage for anti‑obesity GLP‑1s is shrinking in several states even as demand grows. (kff.org)
2) Today’s Top Stories
“Jab‑u‑ary”: Grocery Stores Start Selling for GLP‑1 Appetites
Major UK retailers are launching portion‑controlled, high‑protein meals and “weight management” aisles to match what many GLP‑1 users report: smaller appetites and a preference for protein-forward foods. Some offerings are also premium-priced, raising questions about whether this trend improves health—or just repackages smaller portions as a luxury. (theguardian.com)
Why it matters: Your environment shapes outcomes—food defaults that match your appetite can make adherence easier, but “GLP‑1-friendly” marketing can also inflate costs for basics.
Source: The Guardian (theguardian.com)
Medicaid Coverage Update: Fewer States Cover GLP‑1s for Obesity in January 2026
KFF reports that 13 state Medicaid programs cover GLP‑1s for obesity treatment under fee‑for‑service as of January 2026, down from 16 states as of October 2025. Several states (including California, New Hampshire, Pennsylvania, and South Carolina) eliminated coverage recently, largely citing budget pressure and drug cost. (kff.org)
Why it matters: Coverage is becoming a zip-code lottery—if you’re on (or considering) GLP‑1 therapy, plan for renewals, prior authorizations, and sudden policy shifts.
Source: KFF (kff.org)
California Ends Medi‑Cal Coverage for GLP‑1 Weight‑Loss Drugs (Starting Jan 1, 2026)
California ended Medi‑Cal coverage of GLP‑1s for weight loss as of January 1, 2026, citing projected costs. Coverage remains for certain groups (e.g., under‑21 coverage obligations and diabetes indications), but many adults using GLP‑1s specifically for obesity are now forced to appeal, switch strategies, or pay out of pocket. (sfchronicle.com)
Why it matters: Stopping medication abruptly often leads to weight regain; if coverage changes, you’ll want a “Plan B” that protects health, not just the scale.
Source: San Francisco Chronicle (sfchronicle.com)
Oral Wegovy’s Early Signal: A “Solid Start” as the Pill Race Accelerates
A market report notes Novo Nordisk’s oral Wegovy launched with early prescription traction in its first week, highlighting growing momentum for non-injectable options. Oral formulations could expand access for needle‑averse patients, but real‑world tolerability, adherence rules, and insurance coverage will decide the impact. (investors.com)
Why it matters: Pills could broaden treatment—yet the basics (protein, strength training, sleep) still determine how well results translate into long-term metabolic health.
Source: Investor’s Business Daily (investors.com)
Celebrity Reality Check: Vanessa Williams on Mounjaro, Menopause, and “Not Just Willpower”
Vanessa Williams shared she’s used Mounjaro for two years for menopausal weight changes, framing it as a tool alongside other health interventions. Her story echoes what many midlife women experience: hormonal transitions can meaningfully shift appetite, body composition, and weight regulation despite consistent habits. (people.com)
Why it matters: Menopause isn’t a “discipline problem”—it’s a physiology shift, and the most sustainable approach is often multi‑tool (nutrition + training + medical support when appropriate).
Source: People (people.com)
3) Deep Dive (Weekend Edition): Mindset & Strategy — “Design Your GLP‑1 (or Non‑GLP‑1) Plate for Maintenance”
Whether you’re using a medication (Wegovy/Zepbound/Mounjaro) or not, the goal is the same: lose fat while protecting muscle, energy, and sanity. The biggest long‑term trap I’m seeing right now is this:
Appetite drops → protein drops → strength training slips → muscle drops → metabolism and function take the hit.
The “Small Appetite, High Impact” framework (works on and off GLP‑1s)
1) Anchor protein first (every meal).
If you can only eat a little, make it count. Prioritize protein foods you genuinely tolerate (Greek yogurt, cottage cheese, eggs, tofu/tempeh, fish, chicken, lean beef, beans + a protein add-on). This helps preserve lean mass during weight loss and improves satiety per calorie.
2) Add fiber without turning meals into punishment.
Think: berries, apples, kiwifruit; baby carrots + hummus; bagged salad kits you actually like; lentil soup; high‑fiber wraps. If GLP‑1 GI side effects are an issue, go slow and cook veggies more often.
3) Lift something 2–3x/week (even “minimum effective dose”).
You don’t need a perfect program—consistency beats intensity. Two full‑body sessions weekly can be enough to maintain strength momentum.
4) Expect “food noise” changes—and plan for the emotional whiplash.
Many people grieve the loss of food-as-comfort and feel relief from constant hunger thoughts. Both can be true. If you notice anxiety rising as eating drops, build new “downshift” rituals: a 10‑minute walk, shower, journaling, calling a friend, therapy, or a hobby that uses your hands.
Myth-busting (compassionate but clear):
Myth: “If I’m not hungry, I don’t need to eat.”
Reality: Appetite is a signal, not a full nutrition plan—especially on GLP‑1s. Under‑eating protein and overall energy can backfire via fatigue, muscle loss, constipation, and eventual rebound eating.
Practical action for today (10 minutes):
Write a two‑line emergency plan for days when appetite is low:
- My default protein: ________
- My default fiber: ________
Keep those foods stocked. You’ll thank yourself later.
4) Quick Hits
- FDA previously announced the semaglutide injection shortage was resolved (Wegovy/Ozempic), while noting patients can still see localized pharmacy disruptions as supply moves through the chain. (fda.gov)
- FDA also outlined time-limited enforcement discretion windows (in 2025) for compounding as shortages resolve—worth knowing if you’re navigating compounded products. (fda.gov)
- Advocacy pressure continues: the AMA passed a resolution in 2025 pushing to reduce prior authorization burdens for anti-obesity medications. (endocrine.org)
- Oral GLP‑1 competition is intensifying—watch 2026 for more “pill” headlines and insurance policy reactions. (investors.com)
- If you’re in a state with shifting Medicaid policy, check whether coverage is preserved for diabetes vs obesity indications and what appeals pathways exist. (kff.org)
- Retail trends are following behavior: smaller portions + higher protein are becoming a mainstream product strategy, not just a personal strategy. (theguardian.com)
5) By The Numbers
13 — the number of state Medicaid programs covering GLP‑1s for obesity treatment under fee‑for‑service as of January 2026 (per KFF). (kff.org)
What it means: Access is expanding in some places and retracting in others—coverage is unstable and often paired with prior authorization controls.
Why you should care: If you rely on coverage, the most “metabolic health” thing you can do is also administrative: document outcomes, keep visit notes, and prepare for renewals.
6) Ask The Community
If your appetite dropped suddenly (from GLP‑1s, stress, or a busy season), what’s your go-to “minimum effective” meal that still hits protein and fiber?
7) Tomorrow’s Preview
Medication Monday: The smartest, safest way to respond to changing coverage—step therapy, prior auth playbooks, and what to do if you must taper or pause a GLP‑1 (without spiraling into “all-or-nothing” eating).